search
Back to results

Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia

Primary Purpose

Trigeminal Neuralgia

Status
Completed
Phase
Phase 2
Locations
Malaysia
Study Type
Interventional
Intervention
Lamictal®
Tegretol®
Sponsored by
University of Malaya
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Trigeminal Neuralgia focused on measuring Trigeminal Neuralgia, Lamotrigine, Carbamazepine, Lamictal®, Tegretol®

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of Trigeminal Neuralgia
  • Male; or non-pregnant/non-lactating female
  • Must be willing to cooperate with and understands study instructions
  • Signed informed consent prior to entering study

Exclusion Criteria:

  • psychiatric illness
  • severe liver or cardiovascular disease
  • renal impairment, low white cell count
  • malignancy
  • pregnancy or lactation
  • alcohol or recreational drug abuse
  • and positive tests for human immunodeficiency virus or hepatitis B or C.

Sites / Locations

  • Dept. of OMOP, Faculty of Dentistry, University Malaya.
  • Dept. of Oral Medicine and Oral Pathology, Faculty of Dentistry, University Malaya.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Lamictal®

Tegretol®

Arm Description

Lamictal® was used as the "active" medication in this study.

Tegretol® was employed as the "control" for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®.

Outcomes

Primary Outcome Measures

Pain-relief

Secondary Outcome Measures

Full Information

First Posted
May 27, 2009
Last Updated
June 27, 2010
Sponsor
University of Malaya
search

1. Study Identification

Unique Protocol Identification Number
NCT00913107
Brief Title
Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia
Official Title
Lamotrigine in Trigeminal Neuralgia: Efficacy and Safety in Comparison With Carbamazepine
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Malaya

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to determine the efficacy and safety of lamotrigine in patients with trigeminal neuralgia (TGN).
Detailed Description
Trigeminal Neuralgia (TGN) is a rare form of chronic facial pain shrouded in mystery, although not life threatening, can be excruciating painful and extraordinarily debilitating. Its uniqueness and peculiarity can be ascertained by the fact that TGN may present to and be managed by dentists, neurologists, neurosurgeons, oral surgeons and ear, nose and throat surgeons. The management of TGN is initially medical, with the "gold standard" drug of carbamazepine (CBZ). Whilst CBZ continues to be the treatment of choice, a substantial proportion of patients tolerate this drug poorly, predominantly because of side-effects that include drowsiness, accommodation disorders, hepatitis, elevation in liver enzymes, renal dysfunction, congestive heart failure, delayed multi-organ failure, leucopenia, thrombocytopenia etc. etc. If pain-relief is incomplete with CBZ or it produces adverse side-effects, options include using an alternative second-line medical agent. The drugs suggested to be considered as second-line agents for the treatment of TGN, include: lamotrigine, baclofen, phenytoin, oxcarbazepine, gabapentin, clonazepam, valproate, mexiletine, and topiramate. Lamotrigine (LTG), a novel anticonvulsant, which has not been adequately assessed for its antineuralgic properties. It has a bimodal mechanism of action: inhibits the release of glutamate and aspartate by blocking voltage-sensitive sodium channels antagonistic at neuroexcitatory N-methyl-d-aspartate receptors. It can also acts at and inhibits calcium channels to enhance the gamma- Aminobutyric acid (GABA) synthesis. GABA is an inhibitory amino acid neurotransmitter that decreases neural membrane action potentials and therefore decreases nerve excitability. Glutamate has been implicated in the mechanisms contributing towards phenomenon of chronic pain, such as sensitisation and wind up. LTG through its inhibition of pathological release of glutamate, has the potential towards management of chronic pain, particularly of neuropathic origin. Lamotrigine, therefore has the potential to be a promising new treatment for TGN.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trigeminal Neuralgia
Keywords
Trigeminal Neuralgia, Lamotrigine, Carbamazepine, Lamictal®, Tegretol®

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lamictal®
Arm Type
Experimental
Arm Description
Lamictal® was used as the "active" medication in this study.
Arm Title
Tegretol®
Arm Type
Active Comparator
Arm Description
Tegretol® was employed as the "control" for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®.
Intervention Type
Drug
Intervention Name(s)
Lamictal®
Other Intervention Name(s)
Lamotrigine (generic name for Lamictal®), Carbamazepine (generic name for Tegretol®)
Intervention Description
The regime of prescription for Lamictal® during the clinical trials was as follows: 50 mg twice daily for 10days, followed by, 100 mg twice daily for the next 10days, followed by, 100 mg thrice daily for the next10 days, followed by, 100 mg four times daily for the final 10 days.
Intervention Type
Drug
Intervention Name(s)
Tegretol®
Other Intervention Name(s)
Lamotrigine (generic name for Lamictal®), Carbamazepine (generic name for Tegretol®)
Intervention Description
The regime of prescription for Tegretol® during the clinical trials was as follows: 150 mg twice daily for 10days, followed by, 200 mg thrice daily for the next 10days, followed by, 300 mg thrice daily for the next 10 days, followed by, 300 mg four times daily for the final 10 days.
Primary Outcome Measure Information:
Title
Pain-relief
Time Frame
3-6 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of Trigeminal Neuralgia Male; or non-pregnant/non-lactating female Must be willing to cooperate with and understands study instructions Signed informed consent prior to entering study Exclusion Criteria: psychiatric illness severe liver or cardiovascular disease renal impairment, low white cell count malignancy pregnancy or lactation alcohol or recreational drug abuse and positive tests for human immunodeficiency virus or hepatitis B or C.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Sameer Shaikh, MDSc.
Organizational Affiliation
Faculty of Dentistry, University Malaya
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dept. of OMOP, Faculty of Dentistry, University Malaya.
City
Kuala Lumpur
ZIP/Postal Code
50603
Country
Malaysia
Facility Name
Dept. of Oral Medicine and Oral Pathology, Faculty of Dentistry, University Malaya.
City
Kuala Lumpur
ZIP/Postal Code
50603
Country
Malaysia

12. IPD Sharing Statement

Citations:
PubMed Identifier
21621166
Citation
Shaikh S, Yaacob HB, Abd Rahman RB. Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. J Chin Med Assoc. 2011 Jun;74(6):243-9. doi: 10.1016/j.jcma.2011.04.002. Epub 2011 May 10.
Results Reference
derived

Learn more about this trial

Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia

We'll reach out to this number within 24 hrs